Margaret A. Tucker, M.D.

Scientist Emeritus



9609 Medical Center Drive
Room SG/7E422
Rockville, MD 20850


Research Topics

Dr. Margaret A. Tucker's landmark scientific contributions have substantively improved our understanding of the mechanisms underlying familial cancers, the etiology of melanoma, and predisposition to multiple malignancies. Her research team and collaborators identified the first major susceptibility genes for melanoma. Dr. Tucker and her team published a melanoma atlas, created training videos for the clinical examination of members of high-risk families, developed the first calculator to estimate an individual’s risk of developing melanoma, and more recently launched a website with the first-ever serial collection of dysplastic nevi and melanomas, documenting skin changes over nearly four decades of clinical follow-up.


Dr. Tucker received her M.D. from Harvard Medical School and completed training in internal medicine and medical oncology at Stanford University Medical Center. In her over 40 years at NCI, Dr. Tucker led the Institute’s research program on familial cancers, serving as Director of the DCEG Human Genetics Program. Dr. Tucker retired in June 2018 and was named as a Scientist Emeritus by the NIH Scientific Directors. She remains committed to DCEG, providing crucial scientific advice for ongoing studies in several important research areas, mentoring junior investigators, and offering valuable management insights to DCEG’s leadership team.

Selected Publications

  1. Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldstein A, Goldin L, Lubin J, Wacholder S, Caporaso NE, Bertazzi PA, Tucker MA, Pesatori AC, Landi MT. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst. 2015;107(6):djv059.
  2. Lam CJ, Curtis RE, Dores GM, Engels EA, Caporaso NE, Polliack A, Warren JL, Young HA, Levine PH, Elmi AF, Fraumeni JF Jr, Tucker MA, Morton LM. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. J Clin Oncol. 2015;33(28):3096-104.
  3. Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X, NCI DCEG Cancer Sequencing Working Group., NCI DCEG Cancer Genomics Research Laboratory., French Familial Melanoma Study Group., Bruno W, Pastorino L, Queirolo P, Banuls-Roca J, Garcia-Casado Z, Vaysse A, Mohamdi H, Riazalhosseini Y, Foglio M, Jouenne F, Hua X, Hyland PL, Yin J, Vallabhaneni H, Chai W, Minghetti P, Pellegrini C, Ravichandran S, Eggermont A, Lathrop M, Peris K, Scarra GB, Landi G, Savage SA, Sampson JN, He J, Yeager M, Goldin LR, Demenais F, Chanock SJ, Tucker MA, Goldstein AM, Liu Y, Landi MT. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46(5):482-6.
  4. Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013;22(4):528-32.
  5. Kleinerman RA, Yu CL, Little MP, Li Y, Abramson D, Seddon J, Tucker MA. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30(9):950-7.

Related Scientific Focus Areas

This page was last updated on Wednesday, January 19, 2022